Clinical trials for TKI chemotherapy were first conducted during the late 1990s [108], and since then, their use had been approved for the treatment of several types of cancer: chronic myeloid leukemia [109], gastrointestinal stromal tumor [110], metastatic breast cancer [111], metastatic renal cell carcinoma [112], hepatocellular carcinoma [113], HER2-positive breast cancer [114], metastatic colorectal cancer, non-small cell lung cancer, glioblastoma, ovarian cancer, and cervical cancer [115]. Here, ERBB2 is linked to breast carcinoma.